Vertex Pharmaceuticals Inc. Stock

Price

Target price

/ Tradegate WKN: 882807 / Symbol: VRTX / Name: Vertex / Stock / Biotechnology & Medical Research / Large Cap /

Please give a prediction to see the opinions of the community

sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Your prediction

Vertex Pharmaceuticals Inc. Stock

Vertex Pharmaceuticals Inc. gained 2.500% today.

The stock is an absolute favorite of our community with 45 Buy predictions and no Sell predictions.

With a target price of 467 € there is a slightly positive potential of 19.74% for Vertex Pharmaceuticals Inc. compared to the current price of 390.0 €.

Our community identified positive and negative aspects for Vertex Pharmaceuticals Inc. stock for the coming years. 5 users see the criterium "Worthwhile Investment for the next years" as a plus for the Vertex Pharmaceuticals Inc. stock. On the other hand our users think that "Expected dividend yield" could be a problem in the future.

What does Vertex do?

Pros and Cons of Vertex Pharmaceuticals Inc. in the next few years

Pros

G***** c******* t* c**********

C******** o* t** e**********

W********* I********* f** t** n*** y****

Cons

M***** P*******

B****

S********** s********

Tell us your opinion to access the 'Wisdom of the Crowds'

Your Opinion

Legal notice

Performance of Vertex Pharmaceuticals Inc. vs. its peers

Security	Change(%)	1w	1m	1y	YTD	3y	5y
Vertex Pharmaceuticals Inc.
Incyte Corp.
IQVIA Holdings Inc.
Gilead Sciences Inc

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.

Last updated at 2024-08-01

When evaluating the financial position of Vertex Pharmaceuticals Inc. (symbol: VRTX), it is evident that the company exhibits robust financial health, especially for a player in the Biotechnology & Medical Research sector. As observed from the provided financial statements, Vertex demonstrates strong revenue growth, impressive profitability, and significant cash reserves. This overall positive trend is accompanied by notable investment in research and development, which is critical for sustaining innovation in the biotech field. However, like any investment, a deeper dive into the various financial metrics is essential to identify both advantages and drawbacks.

Strong Revenue Generation: Vertex reported a total revenue of approximately $9.87 billion for 2023, showcasing healthy growth compared to previous years. The quarterly revenue growth rate of 13.3% indicates consistent demand for its products, which is promising for future sales and market expansion.

Impressive Profit Margins: The profit margin stands at around 39.5%, highlighting Vertex's ability to convert sales into profits effectively. Coupled with an operating margin of 45.2%, it reflects efficient management of operational expenses relative to revenue.

Feedback